Lilly’s Donanemab Receives CDSCO Approval for the Treatment of Early Symptomatic Alzheimer’s Disease

▴ Eli Lilly and Company (India) Pvt. Ltd.
Eli Lilly and Company (India) Pvt. Ltd. today announced that the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization for donanemab for the treatment of Alzheimer’s disease (AD) in adults with early symptomatic stages.

New Delhi, November 18, 2025 – Eli Lilly and Company (India) Pvt. Ltd. today announced that the Central Drugs Standard Control Organization (CDSCO) has granted marketing authorization for donanemab (350 mg/20 mL administered every four weeks via intravenous infusion as described in the prescribing information) for the treatment of Alzheimer’s disease (AD) in adults with early symptomatic stages. This includes individuals with mild cognitive impairment (MCI) and those in the mild dementia stage of AD, with confirmed amyloid pathology.1,2

Amyloid is a protein produced naturally in the body that can clump together to create amyloid plaques. The excessive buildup of amyloid plaques in the brain may lead to memory and thinking issues associated with Alzheimer’s disease.3,4 Donanemab is a disease modifying drug that helps the body remove excessive buildup of amyloid plaques and slows the cognitive and functional decline that may diminish people’s ability to remember new information, important dates, and appointments; plan and organize; make meals; use household appliances; manage finances; and be left alone.3-6

“The approval of donanemab marks a significant milestone in our mission to address the urgent needs of people living with Alzheimer’s disease in India,” said Winselow Tucker, president and general manager, Lilly India. “By offering an innovative therapy that targets amyloid plaques and slows cognitive decline, we aim to give patients and their families more time and a better quality of life.7 This underscores Lilly’s commitment to delivering innovative treatments in India to those who need them most.”

Alzheimer’s disease is the most common cause of dementia globally, accounting for 60–70% of cases.8 However, currently, it is highly underdiagnosed. India, with its rapidly aging population, faces a growing health challenge: it is estimated that by 2030, over 8 million people in India will be living with dementia, with Alzheimer’s disease representing the largest share of cases.9 Early diagnosis and treatment are critical to improving patient outcomes and easing the significant burden on families and caregivers.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026